Latest News for MRKR
MARKER THERAPEUTICS, INC. (MRKR) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.21.
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses
HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference,…
Marker Therapeutics' shares jump 114% in three months as early MT-601 data showed strong responses, advanced into dose expansion, and lifted investor confidence.
After reaching an important support level, MARKER THERAPEUTICS, INC. (MRKR) could be a good stock pick from a technical perspective.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MRKR.
U.S. House Trading
No House trades found for MRKR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.